Mirum Pharmaceuticals (MEX:MIRM) Float Percentage Of Total Shares Outstanding : 85.89% (As of Jun. 02, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mirum Pharmaceuticals's float shares is 40.48 Mil. Mirum Pharmaceuticals's total shares outstanding is 47.13 Mil. Mirum Pharmaceuticals's float percentage of total shares outstanding is 85.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mirum Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mirum Pharmaceuticals's Institutional Ownership is 43.44%.

Mirum Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Mirum Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	40.48	/	47.13
	=	85.89%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals (MEX:MIRM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (MEX:MIRM) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

MIRM:USA 08D:Germany

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.